Roche Holding AG Stock
Price
Target price
€388.60
€388.60
1.460%
5.6
1.460%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Roche Holding AG Stock
There is an upward development for Roche Holding AG compared to yesterday, with an increase of €5.60 (1.460%).
Pros and Cons of Roche Holding AG in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Roche Holding AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Roche Holding AG | 1.460% | 0.051% | 7.052% | 35.306% | 6.876% | 57.967% | 57.967% |
| Beximco Pharmaceuticals Ltd. GDR | -0.940% | 2.941% | 16.667% | 22.664% | 17.188% | 20.413% | -40.341% |
| Eledon Pharmaceuticals Inc. | 2.840% | -9.375% | -13.690% | 8.209% | 126.563% | 137.705% | -46.789% |
| SELLAS Life Sciences Group Inc | -2.910% | -12.851% | -25.812% | 502.778% | 206.173% | 479.439% | 20.556% |
Comments
News
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Madrigal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Rezdiffra sales rose 71% year over year to $364.3 million in Q2 2026, with nearly $1.3 billion in
Alnylam Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better.
- Second-quarter revenue surged 74% to approximately $1.2 billion, driven by AMVUTTRA, which
The Hanover Insurance Group Q2 Earnings Call Highlights
The Hanover Insurance Group (NYSE:THG) reported record second-quarter operating performance, citing improved underwriting margins, accelerating premium growth and higher investment income across